And its field-emission application. ACS Appl Mater Interfaces 2011, three:3084090. 25. Zhao F, Duan H, Wang W, Wang J: Synthesis and characterization of magnetic Fe/CNTs composites with controllable Fe nanoparticle concentration. Phys B 2012, 407:2495499. 26. Sirena M, Zimmers A, Haberkorn N, Kaul E, Steren LB, Lesueur J, Wolf T, Gall YL, Grob JJ, Faini G: Direct observation of electronic inhomogeneities induced by point defect disorder in manganite films. J Appl Phys 2010, 107:113903. 27. Geng F, Cong H: Fe-filled carbon nanotube array with higher coercivity. Phys B 2006, 382:30004. 28. Qin DH, Peng Y, Cao L, Li HL: A study of magnetic properties Fex Co1-x alloy nanowire arrays. Chem Phys Lett 2003, 374:66166. 29. Hu X, Yu JC: High-yield synthesis of nickel and nickel phosphide nanowires by means of microwave-assisted processes. Chem Mater 2008, 20:6743749. 30. Kavich DW, Dickerson JH, Mahajan SV, Hasan SA, Park JH: 0Exchange bias of singly inverted FeO/Fe3 O4 core-shell nanocrystals. Phys Rev B 2008, 78:174414. 31. Ji G, Cao J, Zhang F, Xu G, Su H, Tang S, Gu B, Du Y: Nix , Pb1-x nanowire arrays: effects of annealing. J Phys Chem B 2005, 109:171007106. 32. Nogu J, Schuller IK: Exchange bias.Pyrazinamide J Magn Magn Mater 1999, 192:20332. 33. Uyama H, Otani Y, Fukamichi K, Kitakami O, Shimad Y, Echigoya JI: Impact of antiferromagnetic grain size on exchange-coupling field of Cr70 Al30 /Fe19 Ni81 bilayers. Appl Phys Lett 1997, 71:1258260. 34. Saha J, Victora RH: Spontaneous exchange bias: unidirectional anisotropy in an otherwise isotropic method. Phys Rev B 2007, 76:100405(R).doi:ten.1186/1556-276X-8-423 Cite this short article as: Cao et al.: Magnetic properties of fluffy Fe@-Fe2 O3 core-shell nanowires. Nanoscale Study Letters 2013 8:423.
NIH Public AccessAuthor ManuscriptJ Urol. Author manuscript; readily available in PMC 2014 September 01.Published in final edited kind as: J Urol. 2013 April ; 189(four): 1268274. doi:ten.1016/j.juro.2012.10.070.Dobutamine hydrochloride NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptRandomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms In the course of Intravesical Bacillus Calmette-Gu in TreatmentMichael H.PMID:24957087 Johnson, Kenneth G. Nepple*, Vicky Peck, Kathryn Trinkaus, Aleksandra Klim, Gurdarshan S. Sandhu, and Adam S. Kibel, Division of Urologic Surgery (MHJ, KGN, VP, AK, GSS, ASK) and Division of Biostatistics (KT), Washington University School of Medicine, Saint Louis, Missouri, and Brigham and Women’s Hospital, Harvard Health-related College, Boston, Massachusetts (ASK)AbstractPurpose–Intravesical bacillus Calmette-Gu in is used to reduce recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a popular side effect of remedy and often limit remedy tolerance. Whilst anticholinergic medicines may be employed for symptom prophylaxis, to our knowledge they have not been evaluated in a randomized controlled trial. Supplies and Methods–A total of 50 bacillus Calmette-Gu in na e individuals were randomized to 10 mg extended release oxybutynin every day or placebo beginning the day prior to six weekly bacillus Calmette-Gu in therapies. A questionnaire assessing urinary symptoms (frequency, burning on urination, urgency, bladder pain, hematuria), systemic symptoms (flu-like symptoms, fever, arthralgia) and medication negative effects (constipation, blurred vision, dry mouth) was recorded daily throughout the therapeutic course. A linear mixed repeated measures model tested the variations.